Cargando…

1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa

BACKGROUND: VNRX-5133 is a cyclic boronate β-lactamase inhibitor (BLI) currently in clinical development with cefepime to treat multidrug-resistant (MDR) infections caused by ESBL- and carbapenemase-producing Enterobacteriaceae (ENT) and P. aeruginosa (PSA). VNRX-5133 has direct inhibitory activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daigle, Denis, Hamrick, Jodie, Chatwin, Cassandra, Kurepina, Natalia, Kreiswirth, Barry N, Shields, Ryan K, Oliver, Antonio, Clancy, Cornelius J, Nguyen, Minh-Hong, Pevear, Daniel, Xerri, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252657/ http://dx.doi.org/10.1093/ofid/ofy210.1201

Ejemplares similares

1395. Defining the Magnitude of AUC:MIC Driver for Efficacy of the β-Lactamase Inhibitor VNRX-5133 When Combined with Cefepime Against KPC- and VIM/NDM-Producing Enterobacteriaceae and P. aeruginosa
por: Daigle, Denis, et al.
Publicado: (2018)

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
por: Hamrick, Jodie C., et al.
Publicado: (2020)

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
por: Liu, Bin, et al.
Publicado: (2019)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
por: Trout, Robert E., et al.
Publicado: (2021)

1360. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes
por: Hackel, Meredith, et al.
Publicado: (2018)

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
por: Krajnc, Alen, et al.
Publicado: (2019)

203. Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection
por: Hackel, Meredith, et al.
Publicado: (2021)

Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
por: Chatwin, Cassandra L., et al.
Publicado: (2021)

Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor
por: Dowell, James A., et al.
Publicado: (2021)

1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β-Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model
por: Abdelraouf, Kamilia, et al.
Publicado: (2018)

1401. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects
por: Geibel, Brooke, et al.
Publicado: (2018)

1286. Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
por: Mack, Andrew R, et al.
Publicado: (2021)

The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli
por: Roach, Elyse J., et al.
Publicado: (2021)

1263. Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)
por: Avery, Lindsay M, et al.
Publicado: (2020)

1580. Colistin Potentiates the In Vitro Activity of Meropenem–Vaborbactam (M/V) Against Some, but not All KPC-producing Klebsiella pneumoniae (KPC-Kp)
por: Jones, Chelsea E, et al.
Publicado: (2019)

1370. Prevalence and predictors of post-covid-19 (long covid) in India
por: Kumar, Vignesh, et al.
Publicado: (2023)

The appeal of the PDC program
por: Wasow, Thomas
Publicado: (2013)

706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing Klebsiella pneumoniae (Kp)
por: Jones, Chelsea, et al.
Publicado: (2018)

1370. Role of Clindamycin Versus Linezolid for Serious Group A Streptococcal Infections
por: Heil, Emily, et al.
Publicado: (2021)

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1055. ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236
por: Mack, Andrew R, et al.
Publicado: (2021)

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
por: Karlowsky, James A., et al.
Publicado: (2022)

1370. Three of Hearts: A Case Series and Literature Review of Pediatric Purulent Pericarditis
por: Estes, Alyssa, et al.
Publicado: (2020)

The Cell Wall Deacetylases Spy1094 and Spy1370 Contribute to Streptococcus pyogenes Virulence
por: Aspell, Tiger, et al.
Publicado: (2023)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
por: Barnes, Melissa D., et al.
Publicado: (2017)

The PDC framework applied to prosody and disfluency
por: Ferreira, Fernanda
Publicado: (2013)

pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation
por: Duraes, Fernanda V., et al.
Publicado: (2016)

1829. The Paradox of KPC Bearing Strains of Klebsiella pneumoniae with the D179Y Substitution: Resistance to Ceftazidine/Avibactam (CZA) and Susceptibility to Meropenem (MEM)
por: Barnes, Melissa D, et al.
Publicado: (2019)

P1370: A NOVEL GENE THERAPY VECTOR FOR BETA-HEMOGLOBINOPATHIES WITH A SELECTIVE EXPANSION CASSETTE
por: Kirtsou, Alexandra, et al.
Publicado: (2023)

In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales
por: Karlowsky, James A., et al.
Publicado: (2022)

Decays into ${\pi}^+{\pi}^-$ of the $f_0(1370)$ scalar glueball candidate in pp central exclusive production experiments
por: Gastaldi, Ugo, et al.
Publicado: (2018)

Cefepime-induced encephalopathy
por: Kenzaka, Tsuneaki, et al.
Publicado: (2018)

Cefepime-Induced Encephalopathy
por: Keerty, Dinesh, et al.
Publicado: (2021)

Cefepime-Induced Neurotoxicity
por: Saini, Tanjot, et al.
Publicado: (2021)

Cefepime-Induced Delirium
por: Somoza-Cano, Francisco J, et al.
Publicado: (2021)

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2sm59qu66gprh041u92f46u49u